Phase III study of HFT-290

Phase III study of HFT-290 in pediatric patients with cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223853

Enrollment

Registered

2018-04-02

Start date

2018-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

investigational material(s) Generic name etc : fentanyl citrate INN of investigational material : fentanyl citrate Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Pediatric patients confirmed to have various types of cancer.

Exclusion criteria

Exclusion criteria: - Patients with any cutaneous abnormalities at the planned application site that could be aggravated by application of the investigational product. - Patients with serious cardiac, hepatic, or renal dysfunction, serious respiratory disorders, or severe respiratory depression.

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics pharmacokinetics, safety	—

Secondary

Measure	Time frame
efficacy efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026